Figure 1.

Mean plasma JNJ-1802 concentration-time profile of the single ascending oral dose part on a semi-logarithmic scale (part 1, pharmacokinetics data analysis set). JNJ-1802 was administered as a single oral dose at 50 mg (cohort 1), 150 mg (cohort 2), 400 mg (cohort 3), 1200 mg (cohort 4), and 240 mg (cohort 5) under fasted conditions.